Leroy <<<I can't see $2.00 by the end of the year>>>
I feel there are only two scenario that I can see that would put us at or above $2 by years end the 1st would be having a contract in place for more than $50 million with the likes of Battelle or another large biotech company or 2nd a partnership with another large established company with a dual press release stating the partnership. If sales are just increased slightly it just will not cut it there is way too much over head resistance in the share price and there are a lot of people who want out of this stock. You can see from all the chatter some people have lost faith in Bret and the stead decline in the price since july of 2010 regular investor are tired of waiting. At this point even if the company can show progress on the profit front lots of shareholders have had enough and want out once all the weak hands have sold than the share price could climb. You have to realize the share price was trading in the 50 to 35 cent range for a year and a half before it continued down to where we are now. when (if) we get back to that range there will be lots of people getting back to even who will definitly bail. So to get to that $2 area by years end it'll take an event as stated above or a third event like sale of the company (not likely).
Of course we all are disappointed at the share price,but I do believe there is some manipulation going on as well as some outright petulant selling. But that was not my point. I was referring to your post about everyone selling. I think that is hyperbole., my Point being that the vast majority have not sold. Ram
With this thin volume there are a lot of shares out, I don‘t care who‘s holding them.
It just feels too me like the speculation (hope) trade is gone from this stock, the promise has been around too long, the chart has that ominous look, and now only real numbers will resurrect it. It will gradually begin trading on valuation until they can show some tangible evidence of a reason to speculate.
News 
Market Data 
Discover 
AI
